Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.

Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers.

The high morbidity and mortality of patients with esophageal (E) and gastro-esophageal junction (GEJ) cancers, warrants new pre-clinical models for drug testing. The utility of primary tumor xenografts (PTXGs) as pre-clinical models was assessed. Clinicopathological, immunohistochemical markers (p53...

Full description

Bibliographic Details
Main Authors: Lorin Dodbiba, Jennifer Teichman, Andrew Fleet, Henry Thai, Maud H W Starmans, Roya Navab, Zhuo Chen, Hala Girgis, Lawson Eng, Osvaldo Espin-Garcia, Xiaowei Shen, Bizhan Bandarchi, Joerg Schwock, Ming-Sound Tsao, Hala El-Zimaity, Sandy D Der, Wei Xu, Robert G Bristow, Gail E Darling, Paul C Boutros, Laurie E Ailles, Geoffrey Liu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4380353?pdf=render

Internet

http://europepmc.org/articles/PMC4380353?pdf=render

Similar Items